Relationship between maternal methadone dosage and neonatal withdrawal. 2002

Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
Department of Obstetrics & Gynecology, The University of Texas Southwestern Medical Center, Dallas, USA. jodi.s.dashe@drexel.edu

OBJECTIVE To determine whether maternal methadone dosage affects duration and degree of neonatal narcotic withdrawal. METHODS This was a retrospective cohort study of pregnant women with opioid addiction who delivered live-born singletons between April 1990 and April 2001. Inpatient detoxification or outpatient methadone maintenance therapy was offered. Women who had a positive drug screen or whose neonate tested positive for opioids were considered to be supplementing. We evaluated indices of neonatal withdrawal according to the maximum daily methadone dosage in the last week of pregnancy. RESULTS Seventy women with opioid addiction were followed. Median methadone dosage was 20 mg (range 0-150 mg), and 32 infants (46%) were treated for narcotic withdrawal. Among women who received less than 20 mg per day, 20-39 mg per day, and at least 40 mg per day of methadone, treatment for withdrawal occurred in 12%, 44%, and 90% of infants, respectively (P < 0.02). Methadone dosage was also correlated with both duration of neonatal hospitalization and neonatal abstinence score (r(s) =.70 and.73 respectively, both P <.001). Neonates were more likely to experience withdrawal if their mothers were supplementing with heroin, 68% versus 35% (P =.01). Regardless of supplementation, there was a significant relationship between methadone dosage and neonatal withdrawal (P <.05). CONCLUSIONS Maternal methadone dosage was associated with duration of neonatal hospitalization, neonatal abstinence score, and treatment for withdrawal. Heroin supplementation did not alter this dose-response relationship. In selected pregnancies, lowering the maternal methadone dosage was associated with both decreased incidence and severity of neonatal withdrawal.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D008691 Methadone A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3) Amidone,Biodone,Dolophine,Metadol,Metasedin,Methaddict,Methadone Hydrochloride,Methadose,Methex,Phenadone,Phymet,Physeptone,Pinadone,Symoron,Hydrochloride, Methadone
D009293 Opioid-Related Disorders Disorders related to or resulting from abuse or misuse of OPIOIDS. Opiate Addiction,Opiate Dependence,Opioid Misuse,Opioid Use Disorder,Prescription Opioid Abuse,Prescription Opioid Misuse,Addiction, Opioid,Dependence, Opioid,Opiate Abuse,Opioid Abuse,Opioid Addiction,Opioid Dependence,Abuse, Opiate,Abuse, Opioid,Abuse, Prescription Opioid,Addiction, Opiate,Dependence, Opiate,Disorder, Opioid Use,Misuse, Opioid,Misuse, Prescription Opioid,Opiate Abuses,Opioid Abuse, Prescription,Opioid Abuses,Opioid Addictions,Opioid Dependences,Opioid Misuses,Opioid Related Disorders,Opioid Use Disorders,Opioid-Related Disorder,Prescription Opioid Abuses,Prescription Opioid Misuses
D009357 Neonatal Abstinence Syndrome Fetal and neonatal addiction and withdrawal as a result of the mother's dependence on drugs during pregnancy. Withdrawal or abstinence symptoms develop shortly after birth. Symptoms exhibited are loud, high-pitched crying, sweating, yawning and gastrointestinal disturbances. Abstinence Syndrome, Neonatal,Neonatal Withdrawal Syndrome,Passive Addiction, Neonatal,Substance Withdrawal, Neonatal,Neonatal Substance Withdrawal,Abstinence Syndromes, Neonatal,Addiction, Neonatal Passive,Addictions, Neonatal Passive,Neonatal Abstinence Syndromes,Neonatal Passive Addiction,Neonatal Passive Addictions,Neonatal Substance Withdrawals,Neonatal Withdrawal Syndromes,Passive Addictions, Neonatal,Substance Withdrawals, Neonatal,Syndrome, Neonatal Abstinence,Syndrome, Neonatal Withdrawal,Syndromes, Neonatal Abstinence,Syndromes, Neonatal Withdrawal,Withdrawal Syndrome, Neonatal,Withdrawal Syndromes, Neonatal,Withdrawal, Neonatal Substance
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011336 Probability The study of chance processes or the relative frequency characterizing a chance process. Probabilities
D003932 Heroin A narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Diacetylmorphine,Diamorphine,Diacetylmorphine Hydrochloride,Diagesil,Diamorf,Heroin Hydrochloride,Min-I-Jet Morphine Sulphate,Hydrochloride, Diacetylmorphine,Hydrochloride, Heroin,Min I Jet Morphine Sulphate
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
June 1993, Obstetrics and gynecology,
Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
May 1995, The Australian & New Zealand journal of obstetrics & gynaecology,
Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
January 1976, The American journal of drug and alcohol abuse,
Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
August 2003, American journal of obstetrics and gynecology,
Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
October 1977, American journal of obstetrics and gynecology,
Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
September 2010, The Journal of pediatrics,
Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
January 1990, Journal of perinatal medicine,
Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
April 1991, Journal of paediatrics and child health,
Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
January 2013, Neurotoxicology and teratology,
Jodi S Dashe, and Jeanne S Sheffield, and Debora A Olscher, and Sally J Todd, and Gregory L Jackson, and George D Wendel
March 2011, Clinical chemistry,
Copied contents to your clipboard!